Skip to main content
TipRanks
Go Ultimate75% OFF

Ortin Global Ltd (ORTINGLOBE) AI Stock Analysis

0 Followers
IN:ORTINGLOBE

Ortin Global Ltd

(NSE:ORTINGLOBE)

Select Model
Rating:39Underperform
Price Target:INR 12.00â–¼(-4.00% Downside)
Action:downgraded
Date:10/14/26

The score is primarily constrained by weak profitability, persistent operating cash burn, and rising leverage. Technical momentum is also unfavorable, while the negative P/E provides little valuation support. Strong revenue growth is the principal offset.

Positive Factors
Positive Equity BasePositive equity in both reported years offers a residual buffer against operating losses and debt obligations. Although leverage has risen materially, this capital base provides more support than an already-negative equity position and may help preserve financing flexibility over the next several quarters.
Negative Factors
Severe Margin and Profitability DeteriorationThe company is generating revenue at deeply uneconomic margins, with gross profit turning negative and operating and net losses reaching extreme levels. Such deterioration undermines the durability of revenue growth, increases funding needs, and makes a near-term path to self-sustaining earnings difficult.

Ortin Global Ltd (ORTINGLOBE) vs. iShares MSCI India ETF (INDA)

-20%0%20%40%60%IN:ORTINGLOBE+1.30%INDA-5.59%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 105.14M
Dividend Yield
―
Average Volume (3M)
1,510
Price to Earnings (P/E)
-15.4
Beta (1Y)
0.44
Revenue Growth
-52.63%
EPS Growth
29.50%
Country
India
Employees
8
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - Specialty & Generic

Ortin Global Ltd Business Overview & Revenue Model

Company Description

Ortin Global Ltd., established in 1986 and headquartered in Hyderabad, India, is an Indian enterprise specializing in the manufacturing and trading of pharmaceuticals, drugs, and their intermediates. The company, formerly known as Ortin Laboratories...

How the Company Makes Money

null

Ortin Global Ltd Financial Statement Overview

Summary

Revenue growth is strong, but profitability is sharply negative, operating cash burn is widening, free cash flow is not genuinely cash-generative, and rising leverage increases financial risk. The underlying financial scores average below the required minimum, so the component is assigned the floor score of 37.

Income Statement

28Negative

Balance Sheet

45Neutral

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2022
Income Statement
Total Revenue767.00K1.00M3.42M21.11M82.31M60.20M
Gross Profit-1.07M-1.52M1.28M-16.04M35.79M26.31M
EBITDA-8.92M-7.21M-8.23M-63.84M5.50M4.85M
Net Income-9.03M-7.40M-8.46M-80.41M-3.99M-936.00K
Balance Sheet
Total Assets046.47M37.81M66.64M207.05M211.97M
Cash, Cash Equivalents and Short-Term Investments6.06M6.06M3.74M4.59M4.92M2.56M
Total Debt010.05M2.50M18.07M61.44M64.47M
Total Liabilities-12.37M34.10M18.03M38.40M97.48M103.32M
Stockholders Equity12.37M12.37M19.77M28.24M109.57M108.65M
Cash Flow
Free Cash Flow-7.75M-5.60M-4.14M-47.87M20.23M-2.53M
Operating Cash Flow-7.75M-5.62M-4.10M-47.87M21.48M-2.53M
Investing Cash Flow410.00K390.00K-36.00K120.00M-1.25M82.00K
Financing Cash Flow6.79M7.55M3.28M-34.90M-4.71M9.04M

Ortin Global Ltd Technical Analysis

Technical Analysis SentimentNegative
Last Price12.50

Price Trends

50DMA14.37Negative
100DMA15.07Negative
200DMA15.04Negative

Market Momentum

MACD-0.26Negative
RSI45.65Neutral
STOCH70.17Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORTINGLOBE, the sentiment is Negative. The current price of 12.50 is below the 20-day moving average (MA) of 13.08, below the 50-day MA of 14.37, and below the 200-day MA of 15.04, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of 70.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORTINGLOBE.

Ortin Global Ltd Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:ORTINGLOBE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:PARIN:PAR73OutperformINR 1.46B11.27――9.40%34.12%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:BIOFILCHEMIN:BIOFILCHEM47NeutralINR 506.12M105.85――9.31%-82.71%
IN:VIVIMEDLABIN:VIVIMEDLAB46NeutralINR 447.74M-0.24――-39.80%-452.04%
IN:ORTINGLOBEIN:ORTINGLOBE39UnderperformINR 105.55M-15.45――-52.63%29.50%
IN:LASAIN:LASA38UnderperformINR 227.96M-1.28――-95.17%50.07%
IN:MANGALAMIN:MANGALAM37UnderperformINR 459.49M-1.21――-2.37%-92.45%

* General Sector Average

Performance Comparison

0%200%400%IN:ORTINGLOBEIN:BIOFILCHEMIN:LASAIN:MANGALAMIN:PARIN:VIVIMEDLABDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:ORTINGLOBE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:ORTINGLOBEOrtin Global Ltd12.500.584.87%
IN:BIOFILCHEMBiofil Chemicals & Pharmaceuticals Ltd.30.77-8.40-21.44%
IN:LASALasa Supergenerics Ltd.4.33-5.92-57.76%
IN:MANGALAMMangalam Drugs & Organics Ltd.28.18-32.96-53.91%
IN:PARPar Drugs and Chemicals Limited115.5421.4722.82%
IN:VIVIMEDLABVivimed Labs Limited5.500.6012.24%

Ortin Global Ltd Corporate Events

Ortin Global Board Approves Unaudited Results and Proposed Auditor Appointment

Nov 11, 2026

Ortin Global Limited said its board approved unaudited financial results for the quarter and half year ended September 30, 2026, along with the statutory auditors’ limited review report.Mathesh & Ramana resigned as statutory auditors effective Novemb...

Ortin Global Board Approves Proposed Auditor Change, Results

Nov 11, 2026

The release does not specify Ortin Global Limited’s industry, products or services, or market focus.The board approved unaudited financial results for the quarter and half year ended September 30, 2026, along with the statutory auditors’ limited revi...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026